EN DE
Watch Jiangsu Apon Medical Technology Co Ltd Class A for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Jiangsu Apon Medical Technology Co Ltd Class A (300753) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Jiangsu Apon Medical Technology Co Ltd Class A stock ¥15.40, price ¥18.84, that is 18.3% below the price, quality 48 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100003FV4

JA Jiangsu Apon Medical Technology Co Ltd Class A logo Thin data Nov 16, 2026

Jiangsu Apon Medical Technology Co Ltd Class A

300753 · SHE

Expensive (fair value 18% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Generates free cash flow over the last twelve months 
Quality 48/100 
Revenue last quarter 15% below a year ago. 
Fair value ¥15.40 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −5.0 %/yr in CNY) 
Loss-making · -4.4% net margin (TTM) 
Trails peers (0/10) 
Narrow moat 11/100 · thin data
Thin data 
Estimate
Watch Jiangsu Apon Medical Technology Co Ltd Class A for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥43.19 ¥8.48 Fair Value ¥15.40 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ¥8.48 – ¥43.19 · fair‑value band ¥11.55 – ¥19.26 · the ¥18.84 price screens above the ¥15.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.

Follow Jiangsu Apon Medical Technology Co Ltd Class A in your weekly email

Every Wednesday you see whether Jiangsu Apon Medical Technology Co Ltd Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jiangsu Apon Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical devices in China.

Show moreShow less

The company's principal products include microcomputer injection pumps, disposable injection pumps, wireless analgesia management systems, and pulse oximeters, as well as medical devices, such as sensors in the field of pain management and nasal care sprayers.

Jiangsu Apon Medical Technology Co., Ltd. was founded in 2001 and is headquartered in Nantong, China.

Stock analysis

Jiangsu Apon Medical Technology Co Ltd Class A (300753) currently trades at ¥18.84, while our estimate is ¥15.40, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥11.55 (bear) to ¥19.26 (bull), the price of ¥18.84 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Jiangsu Apon Medical Technology Co Ltd Class A reported revenue of 342M CNY in FY2025 versus 461M CNY in FY2021, a compound −7.2%/yr. Reported net income was −24.0M CNY in FY2025.

Key figures

Market cap 2.5B CNY (≈ $371M) Small · P/S ratio 8.15 · EPS (TTM) ¥−0.2300 · Dividend yield 0.4% · Net margin −7.0% · Return on equity −2.8% · Return on assets (EBIT) −0.5% (5-year average) · Operating margin −8.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).

What moves the price

The share trades about 56% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −43% fair-value upside, at −18%, 300753 screens cheaper than that median.

Fair Value

Bear ¥11.55 Fair Value ¥15.40 Bull ¥19.26
Price ¥18.84 · Downside -18.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 17
How much profit the company makes from its sales and capital
Quality Growth 15
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 89
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 49
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−15.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.0%
Start year 2020 (pandemic). Over 10 years: +8.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
25.6% (2020) → −7.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300753 screens overvalued: fair value 18% below the price. Compare with Intuitive Surgical, Inc →

Compare Jiangsu Apon Medical Technology Co Ltd Class A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside −18.3% · Below median
Profitability
Return on assets −2.8% · Bottom 25%
Net margin (12 months) −4.4% · Bottom 25%
Operating margin (12 months) −8.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −14.7% · Bottom 25%
Dividend yield (12 months) 0.4% · Bottom 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 3.70× · Priciest 25%
P/S (12 months) 7.45× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 22
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)7 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $86.06 $131.27 +53% vs 300753
EssilorLuxottica Société anonyme EL €178.80 €196.22 +10% vs 300753
Intuitive Surgical, Inc ISRG $430.53 $353.90 −18% vs 300753
Medline Inc MDLN $37.68 $28.59 −24% vs 300753
Alcon Inc ALC CHF 61.80 CHF 35.08 −43% vs 300753
Becton, Dickinson and Company BDX $215.42 $97.80 −55% vs 300753
Straumann Holding STMN CHF 107.10 CHF 45.50 −58% vs 300753
West Pharmaceutical Services, Inc WST $414.12 $139.22 −66% vs 300753
Sartorius Stedim Biotech S.A DIM €224.20 €54.82 −76% vs 300753
Sartorius Aktiengesellschaft SRT €226.00 €46.44 −79% vs 300753

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jiangsu Apon Medical Technology Co Ltd Class A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jiangsu Apon Medical Technology Co Ltd Class A Fair Value". https://www.fairvalue-calculator.com/stock/300753

Frequently asked questions

Is Jiangsu Apon Medical Technology Co Ltd Class A (300753) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ¥15.40 versus a price of ¥18.84, about 18% lower (overvalued).
What is the fair value of 300753?
Our estimate for Jiangsu Apon Medical Technology Co Ltd Class A is ¥15.40 (as of Nov 16, 2026), built from audited fundamentals. The current price: ¥18.84.
What is the quality score of 300753?
Jiangsu Apon Medical Technology Co Ltd Class A has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Our calculated price target is the estimate of ¥15.40 (as of Nov 16, 2026). Cautious scenario ¥11.55, optimistic scenario ¥19.26. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Jiangsu Apon Medical Technology Co Ltd Class A stock forecast for 2026?
Our estimate puts fair value at ¥15.40, about 18% lower versus a price of ¥18.84 (overvalued). Cautious scenario ¥11.55, optimistic scenario ¥19.26. The calculation is refreshed regularly with new filings.
What is the revenue of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Jiangsu Apon Medical Technology Co Ltd Class A reported trailing-twelve-month revenue of about 332M CNY (latest available figure, as of Nov 16, 2026).
Does Jiangsu Apon Medical Technology Co Ltd Class A pay a dividend?
Jiangsu Apon Medical Technology Co Ltd Class A currently shows a dividend yield of 0.37% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Jiangsu Apon Medical Technology Co Ltd Class A has a dividend yield of 0.4%.
What is the intrinsic value of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jiangsu Apon Medical Technology Co Ltd Class A it is ¥15.40 per share (as of Nov 16, 2026), against a price of ¥18.84.
Is Jiangsu Apon Medical Technology Co Ltd Class A stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 300753 trades above its calculated fair value: price ¥18.84, fair value ¥15.40, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300753?
No. The price is what the market pays today (¥18.84); the fair value is what the company's own numbers justify (¥15.40). For Jiangsu Apon Medical Technology Co Ltd Class A the two are ¥3.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jiangsu Apon Medical Technology Co Ltd Class A worth?
The market values Jiangsu Apon Medical Technology Co Ltd Class A at about 2.5B CNY (market capitalisation, as of Nov 16, 2026). Per share that is ¥18.84; our models calculate a fair value of ¥15.40 per share.
What do the bullish and bearish scenarios say about 300753?
Our models span a range for Jiangsu Apon Medical Technology Co Ltd Class A: cautious scenario ¥11.55, base ¥15.40, optimistic ¥19.26 per share (as of Nov 16, 2026, price ¥18.84). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Balance-sheet figures for Jiangsu Apon Medical Technology Co Ltd Class A (as of Nov 16, 2026): return on equity −2.8%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 300753 from its 52-week high?
Jiangsu Apon Medical Technology Co Ltd Class A trades at ¥18.84, about 56% below its 52-week high of ¥43.19 and 4% above the low of ¥18.16 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ¥15.40 is for.
Which stocks are comparable to Jiangsu Apon Medical Technology Co Ltd Class A?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jiangsu Apon Medical Technology Co Ltd Class A stock attractive at the current price?
The data as of Nov 16, 2026: price ¥18.84, calculated fair value ¥15.40 (−18%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Jiangsu Apon Medical Technology Co Ltd Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The closing price on Nov 17, 2026 was ¥18.84. Our estimate is ¥15.40, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jiangsu Apon Medical Technology Co Ltd Class A right now?
Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Jiangsu Apon Medical Technology Co Ltd Class A (300753) come from?
Earnings per share at Jiangsu Apon Medical Technology Co Ltd Class A fell 21.9 % a year from 2014 to 2024. Broken into its drivers: revenue per share +0.4 %, EBIT margin −16.4 %, tax rate −4.7 %, residual (interest, one-offs) −2.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Jiangsu Apon Medical Technology Co Ltd Class A

How large is the market capitalisation of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The market capitalisation of Jiangsu Apon Medical Technology Co Ltd Class A is 2.5B CNY (≈ $371M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The price-to-sales ratio of Jiangsu Apon Medical Technology Co Ltd Class A is 8.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Earnings per share at Jiangsu Apon Medical Technology Co Ltd Class A are ¥−0.2300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The dividend yield of Jiangsu Apon Medical Technology Co Ltd Class A is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The net margin of Jiangsu Apon Medical Technology Co Ltd Class A is −7.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The return on equity (ROE) of Jiangsu Apon Medical Technology Co Ltd Class A is −2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
On an EBIT basis the return on assets of Jiangsu Apon Medical Technology Co Ltd Class A is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The operating margin of Jiangsu Apon Medical Technology Co Ltd Class A is −8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Revenue at Jiangsu Apon Medical Technology Co Ltd Class A is down 14.7% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Earnings per share at Jiangsu Apon Medical Technology Co Ltd Class A are growing 372% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jiangsu Apon Medical Technology Co Ltd Class A (300753) generate?
The free cash flow of Jiangsu Apon Medical Technology Co Ltd Class A is −6.1M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Jiangsu Apon Medical Technology Co Ltd Class A (300753) hold?
Jiangsu Apon Medical Technology Co Ltd Class A holds more cash than debt, 125M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Jiangsu Apon Medical Technology Co Ltd Class A in the live analysis

One click puts Jiangsu Apon Medical Technology Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.